全文获取类型
收费全文 | 11935篇 |
免费 | 733篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 148篇 |
儿科学 | 306篇 |
妇产科学 | 287篇 |
基础医学 | 1592篇 |
口腔科学 | 353篇 |
临床医学 | 1074篇 |
内科学 | 2181篇 |
皮肤病学 | 94篇 |
神经病学 | 1418篇 |
特种医学 | 269篇 |
外科学 | 1366篇 |
综合类 | 166篇 |
一般理论 | 27篇 |
预防医学 | 1210篇 |
眼科学 | 331篇 |
药学 | 955篇 |
中国医学 | 28篇 |
肿瘤学 | 902篇 |
出版年
2022年 | 47篇 |
2021年 | 137篇 |
2020年 | 78篇 |
2019年 | 154篇 |
2018年 | 204篇 |
2017年 | 151篇 |
2016年 | 167篇 |
2015年 | 183篇 |
2014年 | 294篇 |
2013年 | 493篇 |
2012年 | 678篇 |
2011年 | 751篇 |
2010年 | 416篇 |
2009年 | 400篇 |
2008年 | 800篇 |
2007年 | 842篇 |
2006年 | 820篇 |
2005年 | 885篇 |
2004年 | 856篇 |
2003年 | 858篇 |
2002年 | 837篇 |
2001年 | 105篇 |
2000年 | 61篇 |
1999年 | 114篇 |
1998年 | 158篇 |
1997年 | 149篇 |
1996年 | 135篇 |
1995年 | 115篇 |
1994年 | 99篇 |
1993年 | 117篇 |
1992年 | 98篇 |
1991年 | 79篇 |
1990年 | 65篇 |
1989年 | 65篇 |
1988年 | 65篇 |
1987年 | 47篇 |
1986年 | 57篇 |
1985年 | 72篇 |
1984年 | 119篇 |
1983年 | 84篇 |
1982年 | 112篇 |
1981年 | 126篇 |
1980年 | 96篇 |
1979年 | 62篇 |
1978年 | 57篇 |
1977年 | 52篇 |
1976年 | 43篇 |
1975年 | 39篇 |
1974年 | 43篇 |
1972年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Patrick E. Barta Richard E. Powers Elizabeth H. Aylward Gary A. Chase Gordon J. Harris Peter V. Rabins Larry E. Tune Godfrey D. Pearlson 《Psychiatry Research: Neuroimaging》1997,68(2-3):65-75
Volumes of medial and lateral temporal lobe structures were assessed using magnetic resonance imaging (MRI) in 11 patients with late-life onset schizophrenia (LOS), 18 normal elderly controls and 12 patients with moderate cognitive impairment due to Alzheimer's disease (AD) who had no non-cognitive symptoms. While both patient groups has smaller volumes of several medial temporal regions (e.g. entorhinal cortex, left hippocampus), schizophrenics had significantly smaller anterior superior temporal gyri (STG) than normal controls, but AD patients did not. We have previously demonstrated anterior STG volume to be reduced in early life onset schizophrenia. 相似文献
12.
13.
Pharmacological interactions between serotonin and dopamine on behavior in the squirrel monkey 总被引:2,自引:1,他引:1
The behavioral effects of GBR 12909, a selective dopamine uptake inhibitor, were determined in squirrel monkeys trained to
respond under a fixed-interval (FI) schedule of stimulus termination and a second-order schedule of IV drug self-administration.
Intermediate doses of GBR 12909 increased FI response rate markedly, and the highest dose decreased response rate below control
values. The 5HT uptake inhibitors, alaproclate and fluoxetine, and the 5HT agonist, quipazine, attenuated the behavioral-stimulant
effects of GBR 12909, whereas the 5HT2A/2C antagonist, ritanserin, enhanced the behavioral-stimulant effects of the lowest dose. GBR 12909 reliably maintained self-administration,
and ritanserin increased response rate maintained by the highest dose. The dopamine agonist, quinpirole, increased FI response
rate in only one of three subjects, and ritanserin enhanced the behavioral-stimulant effects of quinpirole in that subject.
The dopamine agonist, apomorphine, only decreased FI response rate, and ritanserin did not alter its behavioral effects. The
pharmacological profile of GBR 12909 administered alone and in combination with selective 5HT drugs in the present study was
similar to that obtained previously with cocaine, further demonstrating that 5HT can reliably modulate the behavioral effects
of psychomotor stimulants with prominent dopaminergic actions.
Received: 9 July 1996 / Final version: 22 November 1996 相似文献
14.
This paper was originally developed by Calu Lester, the founder of KWICFAN, which took a novel approach to grass roots AIDS education in the black community. Calu died of AIDS before completing the work and the paper was completed by Larry L. Saxxon, who was both a friend of Calu's and an AIDS program consultant.
The paper presents a critical perspective of black America's response to the AIDS epidemic. The findings are frightening. Denial within the black community, coupled with a lack of support from the agencies responsible for funding AIDS education, has created a potential epidemiological nightmare. IV drug use continues to be a critical problem of frightening magnitude, allowing an efficient vehicle of HIV transmission. Most sadly of all, the social conditions that create and perpetuate the problematic drug abuse patterns still continue in black America. Black people are clearly becoming the new face of AIDS. 相似文献
The paper presents a critical perspective of black America's response to the AIDS epidemic. The findings are frightening. Denial within the black community, coupled with a lack of support from the agencies responsible for funding AIDS education, has created a potential epidemiological nightmare. IV drug use continues to be a critical problem of frightening magnitude, allowing an efficient vehicle of HIV transmission. Most sadly of all, the social conditions that create and perpetuate the problematic drug abuse patterns still continue in black America. Black people are clearly becoming the new face of AIDS. 相似文献
15.
Dr. Paul O. Gubbins Pharm.D. Dr. Donna J. Occhipinti Pharm.D. Dr. Larry H. Danziger Pharm.D. 《Pharmacotherapy》1994,14(4):463-470
Study Objective . To determine the influence of treatment on the microbiologic outcome of funguria. Design . Retrospective case series. Setting . A 300-bed tertiary care teaching hospital in a large metropolitan area. Subjects . 141 hospitalized patients, 18 years of age or older, with at least one urine culture positive (≥ 102 cfu/ml) for fungi. Interventions . Retrospective review of medical records to determine the microbiologic outcome of funguria. Main Results . Funguria developed rapidly in individuals with known predisposing factors. Urinalysis did not routinely detect the presence of fungi or pyuria. Symptoms such as fever, dysuria, and frequency were generally absent. Funguria persisted whether it was due to Candida albicans or non-albicans species. There were no statistical differences in the microbiologic outcomes of treated and untreated funguria. Conclusions . Funguria is a rapidly developing, often benign and persistent process. Minimizing predisposing risks, such as removing indwelling urinary catheters, is beneficial in its management. Pharmacologic treatment of funguria due to C. albicans or non-albicans species does not influence the microbiologic outcome. 相似文献
16.
Dr. James Hui Ph.D. Dr. Yow-Ming C. Wang Ph.D. Dr. Appavu Chandrasekaran Ph.D. Dr. Douglas R. Geraets Pharm.D. Dr. James H. Caldwell M.D. Dr. Larry W. Robertson Ph.D. Dr. Richard H. Reuning Ph.D. 《Pharmacotherapy》1994,14(5):607-612
Study Objective . To compare digoxin tablets and liquid-filled capsules with respect to excretion of the drug and its metabolites in urine and feces at steady state. Design . A randomized, crossover trial, each period lasting 3 weeks, with no washout period. Setting . A university hospital. Patients . Six patients, five of whom were elderly, with histories of gastrointestinal disorders, such as hypochlorhydria, intestinal bacterial overgrowth, and inflammatory bowel disease. Interventions . The patients received digoxin once/day in either tablet or capsule form for 3 weeks, and then were switched to the other formulation. Total urinary and fecal excretion from the last 3 days of each regimen were analyzed for the drug and metabolites. Measurements and Main Results . No statistically significant differences were found between tablets and capsules in recovery of digoxin or its metabolites in urine or feces (p=0.05). One subject had a 4-fold increase in urinary drug excretion and 50% decrease in fecal excretion after taking the capsules compared with tablets. Intersubject variability in extent and type of metabolite excretion was greater than intrasubject variability. Conclusions . Fecal analyses may be an accurate way to classify patients as formers of digoxin reduction products. 相似文献
17.
Choc Miles G. Hsuan Francis Honigfeld Gilbert Robinson William T. Ereshefsky Larry Crismon Miles L. Saklad Stephen R. Hirschowitz Jack Wagner Richard 《Pharmaceutical research》1990,7(4):347-351
Clozapine plasma levels were monitored in 16 patients during a series of three consecutive treatments (single dose-multiple dose-single dose). Each patient received a single 75-mg dose (3 x 25 mg) with clozapine tablets, and serial plasma samples were collected over 48 hr after the dose. At 48 hr, a multiple-dose regimen was started, consisting of an initial dose escalation period followed by dosing at a constant regimen for at least 6 days. After the last dose, serial plasma samples were again obtained over 72 hr. Drug was then withheld for at least 7 days, a final single 75-mg dose was given, and plasma sampling was repeated. A subset of the patient population (N = 7) was used to test for a food effect during the single-dose treatments. The pharmacokinetic parameters between the initial and the final single dose periods were not significantly different. Similarly, there were no differences within patients when given the dose after fasting (fed 1 hr after dose) or with a meal. In contrast, the terminal elimination rate differed between the single-dose and the multiple-dose treatments (t1/2 m3 = 7.9 hr single dose and 14.2 hr multiple dose) (P less than 0.05) and the dose-normalized area under the plasma concentration/time curves increased 27% with multiple dosing. Since a previous study in patients (Choc et al., Pharm. Res. 4:402-405, 1987) showed dose proportionality of clozapine plasma concentrations during multiple-dose regimens, the present results cannot be described by Michaelis-Menten kinetics. 相似文献
18.
19.
Larry R. Churchill 《The Hastings Center report》1987,17(2):39-41
Book reviewed in this article: The Needs of Strangers . By Michael Ignatieff. The Health Economy . By Victor Fuchs. Just Health Care . By Norman Daniels 相似文献
20.
Jacobo E Mintzer Larry E Tune Christopher D Breder René Swanink Ronald N Marcus Robert D McQuade Andy Forbes 《The American journal of geriatric psychiatry》2007,15(11):918-931
OBJECTIVE: To assess the efficacy and safety of aripiprazole for psychosis associated with Alzheimer dementia (AD). METHODS: In this double-blind, multicenter study, 487 institutionalized patients with psychosis associated with AD were randomized to placebo or aripiprazole, 2, 5 or 10 mg/day. Primary efficacy assessment was the mean change from baseline to week 10 on the Neuropsychiatric Inventory-Nursing Home (NPI-NH) version Psychosis Subscale score. Secondary measures included NPI-NH Total, Clinical Global Impression-Severity of Illness (CGI-S), Brief Psychiatric Rating Scale (BPRS) Core and Total, and the Cohen-Mansfield Agitation Inventory (CMAI) scores. RESULTS: Aripiprazole 10 mg/day showed significantly greater improvements (mean change [2 x SD]) than placebo on the NPI-NH Psychosis Subscale (-6.87 [8.6] versus -5.13 [10.0]; F = 6.29, df = 1, 422, p = 0.013 by analysis of covariance [ANCOVA]); CGI-S (-0.72 [1.8] versus -0.46 [1.6]; F = 4.68, df = 1, 419, p = 0.031 [ANCOVA]); BPRS Total (-7.12 [18.4] versus -4.17 [21.6]; F = 4.72, df = 1, 399, p = 0.030 [ANCOVA]); BPRS Core (-3.07 [6.9] versus -1.74 [7.8]; F = 7.30, df = 1, 407, p = 0.007 [ANCOVA]); CMAI (-10.96 [22.6] versus -6.64 [28.6]; F = 5.23, df = 1, 410, p = 0.023 [ANCOVA]), and NPI-NH Psychosis response rate (65 versus 50%; chi(2) = 5.52, df = 1, p = 0.019 [CMH]). Aripiprazole 5 mg/day showed significant improvements versus placebo on BPRS and CMAI scores. Aripiprazole 2 mg/day was not efficacious. Cerebrovascular adverse events were reported: aripiprazole 2 mg/day, N = 1; 5 mg/day, N = 2; 10 mg/day, N = 4; placebo, N = 0. No deaths in any group (aripiprazole 2 mg/day, 3%; 5 mg/day, 2%; 10 mg/day, 7%; placebo, 3%) were considered to be treatment-related. CONCLUSION: Aripiprazole 10 mg/day was efficacious and safe for psychosis associated with AD, significantly improving psychotic symptoms, agitation, and clinical global impression. However, clinicians should be aware of the safety considerations of atypical antipsychotic uses in this population. 相似文献